~ Buy the SYMBICORT AEROSPHERE (budesonide; formoterol fumarate) Drug Profile, 2024 PDF Report in the Report Store ~

SYMBICORT AEROSPHERE Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Symbicort Aerosphere, and what generic alternatives are available?

Symbicort Aerosphere is a drug marketed by Astrazeneca and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and eighty-seven patent family members in thirty-two countries.

The generic ingredient in SYMBICORT AEROSPHERE is budesonide; formoterol fumarate. There are twenty-two drug master file entries for this compound. Additional details are available on the budesonide; formoterol fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Symbicort Aerosphere

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 28, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Subscribe

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for SYMBICORT AEROSPHERE?
What are the global sales for SYMBICORT AEROSPHERE?
What is Average Wholesale Price for SYMBICORT AEROSPHERE?

Summary for SYMBICORT AEROSPHERE

International Patents:	187
US Patents:	2
Applicants:	1
NDAs:	1
DailyMed Link:	SYMBICORT AEROSPHERE at DailyMed

Drug patent expirations by year for SYMBICORT AEROSPHERE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SYMBICORT AEROSPHERE

Generic Entry Date for SYMBICORT AEROSPHERE^: ⤷ Subscribe* Constraining patent/regulatory exclusivity: 10,716,753 NDA: 216579 Dosage: AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for SYMBICORT AEROSPHERE

SYMBICORT AEROSPHERE is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SYMBICORT AEROSPHERE is ⤷ Subscribe.

This potential generic entry date is based on patent 10,716,753.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes	10,716,753	⤷ Subscribe	Y			⤷ Subscribe
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes	9,415,009	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for SYMBICORT AEROSPHERE

When does loss-of-exclusivity occur for SYMBICORT AEROSPHERE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 6621
Patent: COMPOSICIONES PARA EL SUMINISTRO DE ANTAGONISTAS MUSCARINICOS DE ACCION PROLONGADA Y AGONISTA DEL RECEPTOR ADRENERGICO B2 DE ACCION PROLONGADA. METODO DE TRATAMIENTO. SISTEMAS ASOCIADOS. INHALADOR DOSIFICADOR
Estimated Expiration: ⤷ Subscribe

Patent: 6806
Patent: COMPOSICIONES PARA EL SUMINISTRO DE AGENTES ACTIVOS MEDIANTE LAS VIAS RES-PIRATORIAS, Y METODOS Y SISTEMAS ASOCIADOS, COSUSPENSION, INHALADOR DOSIFI-CADOR
Estimated Expiration: ⤷ Subscribe

Patent: 6807
Patent: COMPOSICIONES METODOS Y SISTEMAS PARA EL SUMINISTRO DE DOS O MAS AGENTES ACTIVOS MEDIANTE LAS VIAS RESPIRATORIAS. METODO DE PREPARACION COMPOSICION
Estimated Expiration: ⤷ Subscribe

Patent: 1758
Patent: COMPOSICIÓN FARMACÉUTICA QUE PUEDE SUMINISTRARSE DESDE UN INHALADOR DOSIFICADOR
Estimated Expiration: ⤷ Subscribe

Patent: 2477
Patent: COMPOSICIONES PARA EL SUMINISTRO DE AGENTES ACTIVOS MEDIANTE LAS VÍAS RESPIRATORIAS, Y MÉTODOS Y SISTEMAS ASOCIADOS
Estimated Expiration: ⤷ Subscribe

Patent: 2478
Patent: COMPOSICIONES PARA EL SUMINISTRO PULMONAR DE ANTAGONISTAS MUSCARÍNICOS DE ACCIÓN PROLONGADA Y AGONISTAS DEL RECEPTOR ADRENÉRGICO b₂ DE ACCIÓN PROLONGADA, Y MÉTODOS Y SISTEMAS ASOCIADOS
Estimated Expiration: ⤷ Subscribe

Australia

Patent: 10253770
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 10253776
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 10253950
Patent: Respiratory delivery of active agents
Estimated Expiration: ⤷ Subscribe

Patent: 15201037
Patent: Respiratory delivery of active agents
Estimated Expiration: ⤷ Subscribe

Patent: 17201709
Patent: Compositions, methods & systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷ Subscribe

Patent: 18282272
Patent: COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS
Estimated Expiration: ⤷ Subscribe

Patent: 20210160
Patent: COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS
Estimated Expiration: ⤷ Subscribe

Brazil

Patent: 1011220
Patent: composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada.
Estimated Expiration: ⤷ Subscribe

Patent: 1011229
Patent: co-suspensão, inalador de dose medida, e, métodos de preparação de um inalador de dose medida, de dispensação respiratória de um agente ativo a um paciente, e para tratar de um paciente.
Estimated Expiration: ⤷ Subscribe

Patent: 1011508
Patent: composição farmacêutica, métodos para tratar uma doença ou distúrbio pulmonar em um paciente ou população de pacientes, e para dispensação respiratória de um agente ativo a um paciente, e, inalador de dose medida.
Estimated Expiration: ⤷ Subscribe

Canada

Patent: 63936
Patent: COMPOSITIONS PERMETTANT L'ADMINISTRATION DE PRINCIPES ACTIFS PAR VOIE RESPIRATOIRE ET METHODES ET SYSTEMES ASSOCIES (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 63939
Patent: COMPOSITIONS PERMETTANT L'ADMINISTRATION PAR VOIE PULMONAIRE D'ANTAGONISTES, A ACTION PROLONGEE, DES RECEPTEURS MUSCARINIQUES ET D'AGONISTES, A ACTION PROLONGEE, DES RECEPTEURS ADRENERGIQUES B2 ET METHODES ET SYSTEMES ASSOCIES (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 63941
Patent: COMPOSITIONS, METHODES ET SYSTEMES PERMETTANT UNE ADMINISTRATION PAR VOIE RESPIRATOIRE DE DEUX PRINCIPES ACTIFS OU PLUS (COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

China

Patent: 2458364
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 2596176
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 2753152
Patent: Compositions, methods & systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷ Subscribe

Patent: 5193773
Patent: Respiratory delivery of active agents
Estimated Expiration: ⤷ Subscribe

Patent: 7412212
Patent: 经肺递送长效毒蕈碱拮抗剂及长效β₂肾上腺素能受体激动剂的组合物及相关方法与系统 (Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta2 adrenergic receptor agonists and associated methods and systems)
Estimated Expiration: ⤷ Subscribe

Patent: 7669664
Patent: 经呼吸递送活性剂的组合物及相关方法和系统 (Compositions For Respiratory Delivery Of Active Agents And Associated Methods And Systems)
Estimated Expiration: ⤷ Subscribe

Croatia

Patent: 0161098
Estimated Expiration: ⤷ Subscribe

Patent: 0161101
Estimated Expiration: ⤷ Subscribe

Patent: 0161102
Estimated Expiration: ⤷ Subscribe

Patent: 0200166
Estimated Expiration: ⤷ Subscribe

Patent: 0200260
Estimated Expiration: ⤷ Subscribe

Patent: 0200298
Estimated Expiration: ⤷ Subscribe

Cyprus

Patent: 18030
Estimated Expiration: ⤷ Subscribe

Patent: 18034
Estimated Expiration: ⤷ Subscribe

Patent: 18040
Estimated Expiration: ⤷ Subscribe

Patent: 22732
Estimated Expiration: ⤷ Subscribe

Patent: 22749
Estimated Expiration: ⤷ Subscribe

Patent: 22807
Estimated Expiration: ⤷ Subscribe

Patent: 19031
Estimated Expiration: ⤷ Subscribe

Patent: 21012
Estimated Expiration: ⤷ Subscribe

Denmark

Patent: 35023
Estimated Expiration: ⤷ Subscribe

Patent: 35024
Estimated Expiration: ⤷ Subscribe

Patent: 35025
Estimated Expiration: ⤷ Subscribe

Patent: 06149
Estimated Expiration: ⤷ Subscribe

Patent: 11926
Estimated Expiration: ⤷ Subscribe

Patent: 11927
Estimated Expiration: ⤷ Subscribe

European Patent Office

Patent: 35023
Patent: COMPOSITIONS PERMETTANT L'ADMINISTRATION PAR VOIE PULMONAIRE D'ANTAGONISTES, À ACTION PROLONGÉE, DES RÉCEPTEURS MUSCARINIQUES ET D'AGONISTES, À ACTION PROLONGÉE, DES RÉCEPTEURS ADRÉNERGIQUES 2 ET MÉTHODES ET SYSTÈMES ASSOCIÉS (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA 2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 35024
Patent: COMPOSITIONS PERMETTANT L'ADMINISTRATION DE PRINCIPES ACTIFS PAR VOIE RESPIRATOIRE ET MÉTHODES ET SYSTÈMES ASSOCIÉS (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 35025
Patent: ADMINISTRATION PAR VOIE RESPIRATOIRE DE PRINCIPES ACTIFS (RESPIRATORY DELIVERY OF ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Patent: 06149
Patent: COMPOSITIONS POUR L'ADMINISTRATION PAR VOIE PULMONAIRE D'ANTAGONISTES MUSCARINIQUES ET AGONISTES DU RÉCEPTEUR ADRÉNERGIQUE BÉTA-2 À ACTION PROLONGÉE, PROCÉDÉS ET SYSTÈMES ASSOCIÉS (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA-2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 11926
Patent: COMPOSITIONS, PROCÉDÉS ET SYSTÈMES POUR UNE ADMINISTRATION RESPIRATOIRE DE DEUX OU DE PLUSIEURS AGENTS ACTIFS (COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Patent: 11927
Patent: COMPOSITIONS POUR ADMINISTRATION RESPIRATOIRE D'AGENTS ACTIFS ET MÉTHODES ET SYSTÈMES ASSOCIÉS (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

France

Patent: C1040
Estimated Expiration: ⤷ Subscribe

Hong Kong

Patent: 69026
Patent: 用於經由肺部遞送長效蕈毒鹼拮抗劑及長效β 腎上腺素受體激動劑之組成物，及相關方法及系統 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 69027
Patent: 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 69307
Patent: 經由呼吸道遞送活性藥劑 (RESPIRATORY DELIVERY OF ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Patent: 18867
Patent: 活性劑的呼吸遞送 (RESPIRATORY DELIVERY OF ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Patent: 44669
Patent: 經肺遞送長效毒蕈堿拮抗劑及長效β2腎上腺素能受體激動劑的組合物及相關方法與系統 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING β2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 47095
Patent: 經呼吸遞送活性劑的組合物及相關方法和系統 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Hungary

Patent: 29532
Estimated Expiration: ⤷ Subscribe

Patent: 31229
Estimated Expiration: ⤷ Subscribe

Patent: 31283
Estimated Expiration: ⤷ Subscribe

Patent: 47803
Estimated Expiration: ⤷ Subscribe

Patent: 47823
Estimated Expiration: ⤷ Subscribe

Patent: 47834
Estimated Expiration: ⤷ Subscribe

Patent: 900031
Estimated Expiration: ⤷ Subscribe

Patent: 100018
Estimated Expiration: ⤷ Subscribe

Israel

Patent: 6466
Patent: תכשירים לנתינה למערכת הנשימה של גורמים פעילים ושיטות ומערכות קשורות (Compositions for respiratory delivery of active agents and associated methods and systems)
Estimated Expiration: ⤷ Subscribe

Patent: 6467
Patent: תרכובות פרמצבטיות למתן באמצעות משאף מינוני המכילות גליקופירולט או פורמוטרול ושמושן לטיפול במחלות נשימתיות (Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate or formoterol and their use in treatment of pulmonary diseases)
Estimated Expiration: ⤷ Subscribe

Patent: 6468
Patent: תרכובות פרמצבטיות למתן באמצעות משאף מינוני המכילות גליקופירולט ופורמוטרול ושמושן לטיפול במחלות נשימתיות (Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate and formoterol and their use in treatment of pulmonary diseases)
Estimated Expiration: ⤷ Subscribe

Japan

Patent: 23383
Estimated Expiration: ⤷ Subscribe

Patent: 73012
Estimated Expiration: ⤷ Subscribe

Patent: 73013
Estimated Expiration: ⤷ Subscribe

Patent: 69639
Estimated Expiration: ⤷ Subscribe

Patent: 89356
Estimated Expiration: ⤷ Subscribe

Patent: 48645
Estimated Expiration: ⤷ Subscribe

Patent: 92124
Estimated Expiration: ⤷ Subscribe

Patent: 76734
Estimated Expiration: ⤷ Subscribe

Patent: 12528199
Estimated Expiration: ⤷ Subscribe

Patent: 12528200
Estimated Expiration: ⤷ Subscribe

Patent: 12528792
Estimated Expiration: ⤷ Subscribe

Patent: 15187108
Patent: 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 15199735
Patent: ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 (COMPOSITION, METHOD AND SYSTEM FOR DELIVERING TWO OR MORE ACTIVATORS TO RESPIRATORY ORGAN)
Estimated Expiration: ⤷ Subscribe

Patent: 16041713
Patent: 長時間作用性のムスカリン拮抗剤および長時間作用性のΒ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 17222706
Patent: ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 (COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Patent: 18008942
Patent: 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 (COMPOSITION FOR RESPIRATORY DELIVERY OF ACTIVE AGENT, AND RELATED METHOD AND SYSTEM)
Estimated Expiration: ⤷ Subscribe

Patent: 18048150
Patent: 長時間作用性のムスカリン拮抗剤および長時間作用性のΒ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS, AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 19108369
Patent: 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Lithuania

Patent: 435024
Estimated Expiration: ⤷ Subscribe

Patent: 435025
Estimated Expiration: ⤷ Subscribe

Patent: 2019014
Estimated Expiration: ⤷ Subscribe

Patent: 2021511
Estimated Expiration: ⤷ Subscribe

Patent: 35023
Estimated Expiration: ⤷ Subscribe

Patent: 35024
Estimated Expiration: ⤷ Subscribe

Patent: 35025
Estimated Expiration: ⤷ Subscribe

Patent: 06149
Estimated Expiration: ⤷ Subscribe

Patent: 11926
Estimated Expiration: ⤷ Subscribe

Patent: 11927
Estimated Expiration: ⤷ Subscribe

Luxembourg

Patent: 0124
Estimated Expiration: ⤷ Subscribe

Patent: 0208
Estimated Expiration: ⤷ Subscribe

Mexico

Patent: 7126
Patent: ADMINISTRACION RESPIRATORIA DE AGENTES ACTIVOS. (RESPIRATORY DELIVERY OF ACTIVE AGENTS.)
Estimated Expiration: ⤷ Subscribe

Patent: 0163
Patent: COMPOSICIONES PARA SUMINISTRO RESPIRATORIO DE AGENTES ACTIVOS Y METODOS Y SISTEMAS ASOCIADOS. (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷ Subscribe

Patent: 0164
Patent: COMPOSICIONES PARA SUMINISTRO PULMONAR DE ANTAGONISTAS MUSCARÍNICOS DE ACCIÓN PROLONGADA Y AGONISTAS DE RECEPTOR B2 ADRENÉRGICO DE ACCIÓN PROLONGADA Y MÉTODOS Y SISTEMAS ASOCIADOS. (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷ Subscribe

Patent: 11012684
Patent: COMPOSICIONES PARA SUMINISTRO RESPIRATORIO DE AGENTES ACTIVOS Y METODOS Y SISTEMAS ASOCIADOS. (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷ Subscribe

Patent: 11012685
Patent: COMPOSICIONES PARA SUMINISTRO PULMONAR DE ANTAGONISTAS MUSCARINICOS DE ACCION PROLONGADA Y AGONISTAS DE RECEPTOR B2 ADRENERGICO DE ACCION PROLONGADA Y METODOS Y SISTEMAS ASOCIADOS. (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷ Subscribe

Patent: 11012783
Patent: ADMINISTRACION RESPIRATORIA DE AGENTES ACTIVOS. (RESPIRATORY DELIVERY OF ACTIVE AGENTS.)
Estimated Expiration: ⤷ Subscribe

Patent: 20004077
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE LA COMBINACIÓN DE ALBUTEROL Y BUDESÓNIDA, ADAPTADA PARA EL SUMINISTRO RESPIRATORIO MEDIANTE UN INHALADOR DE DOSIS MEDIDA Y EL USO DE LAS MISMAS PARA EL TRATAMIENTO DE TRASTORNOS PULMONARES. (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷ Subscribe

Montenegro

Patent: 631
Patent: SASTAVI ZA ISPORUKU AKTIVNIH AGENASA U DISAJNE PUTEVE I POVEZANI POSTUPCI I SISTEMI (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Netherlands

Patent: 0995
Estimated Expiration: ⤷ Subscribe

Norway

Patent: 19026
Estimated Expiration: ⤷ Subscribe

Patent: 21019
Estimated Expiration: ⤷ Subscribe

Philippines

Patent: 017500778
Patent: COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS
Estimated Expiration: ⤷ Subscribe

Poland

Patent: 35023
Estimated Expiration: ⤷ Subscribe

Patent: 35024
Estimated Expiration: ⤷ Subscribe

Patent: 35025
Estimated Expiration: ⤷ Subscribe

Patent: 06149
Estimated Expiration: ⤷ Subscribe

Patent: 11926
Estimated Expiration: ⤷ Subscribe

Patent: 11927
Estimated Expiration: ⤷ Subscribe

Portugal

Patent: 35023
Estimated Expiration: ⤷ Subscribe

Patent: 35024
Estimated Expiration: ⤷ Subscribe

Patent: 35025
Estimated Expiration: ⤷ Subscribe

Patent: 06149
Estimated Expiration: ⤷ Subscribe

Patent: 11926
Estimated Expiration: ⤷ Subscribe

Patent: 11927
Estimated Expiration: ⤷ Subscribe

Russian Federation

Patent: 80315
Patent: КОМПОЗИЦИИ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ АКТИВНЫХ ВЕЩЕСТВ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE SUBSTANCES AND METHODS AND SYSTEMS CONNECTED THEREWITH)
Estimated Expiration: ⤷ Subscribe

Patent: 86297
Patent: КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ ДВУХ ИЛИ БОЛЕЕ АКТИВНЫХ АГЕНТОВ (COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Patent: 13404
Patent: КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ В2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC RECEPTOR ANTAGONISTS AND LONG-ACTING B2-ADRENERGIC RECEPTOR AGONISTS AND METHODS AND SYSTEMS ASSOCIATED THEREWITH)
Estimated Expiration: ⤷ Subscribe

Patent: 51771
Patent: КОМПОЗИЦИИ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ АКТИВНЫХ ВЕЩЕСТВ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE SUBSTANCES AND METHODS AND SYSTEMS ASSOCIATED THEREWITH)
Estimated Expiration: ⤷ Subscribe

Patent: 11152960
Patent: КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ β-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷ Subscribe

Patent: 11154083
Patent: КОМПОЗИЦИИ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ АКТИВНЫХ ВЕЩЕСТВ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷ Subscribe

Patent: 11154148
Patent: КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ ДВУХ ИЛИ БОЛЕЕ АКТИВНЫХ АГЕНТОВ
Estimated Expiration: ⤷ Subscribe

Patent: 15151358
Patent: КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ В2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷ Subscribe

Patent: 16107464
Patent: КОМПОЗИЦИИ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ АКТИВНЫХ ВЕЩЕСТВ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷ Subscribe

Patent: 16117972
Patent: КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ ДВУХ ИЛИ БОЛЕЕ АКТИВНЫХ АГЕНТОВ
Estimated Expiration: ⤷ Subscribe

Patent: 20102859
Patent: КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ B2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷ Subscribe

San Marino

Patent: 01600326
Patent: DISTRIBUZIONE RESPIRATORIA DI PRINCIPI ATTIVI
Estimated Expiration: ⤷ Subscribe

Patent: 01600327
Patent: COMPOSIZIONI PER IL RILASCIO POLMONARE DI ANTAGONISTI MUSCARINICI AD AZIONE PROLUNGATA E DI AGONISTI DEL RECETTORE ADRENERGICO BETA 2 AD AZIONE PROLUNGATA E METODI E SISTEMI ASSOCIATI
Estimated Expiration: ⤷ Subscribe

Patent: 01600329
Patent: COMPOSIZIONI PER LA DISTRIBUZIONE RESPIRATORIA DI PRINCIPI ATTIVI E METODI E SISTEMI ASSOCIATI
Estimated Expiration: ⤷ Subscribe

Slovenia

Patent: 35023
Estimated Expiration: ⤷ Subscribe

Patent: 35024
Estimated Expiration: ⤷ Subscribe

Patent: 35025
Estimated Expiration: ⤷ Subscribe

Patent: 06149
Estimated Expiration: ⤷ Subscribe

Patent: 11926
Estimated Expiration: ⤷ Subscribe

Patent: 11927
Estimated Expiration: ⤷ Subscribe

South Africa

Patent: 1108275
Patent: RESPIRATORY DELIVERY OF ACTIVE AGENTS
Estimated Expiration: ⤷ Subscribe

Patent: 1208100
Patent: COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS
Estimated Expiration: ⤷ Subscribe

Patent: 1208101
Patent: COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS
Estimated Expiration: ⤷ Subscribe

Patent: 1208102
Patent: RESPIRATORY DELIVERY OF ACTIVE AGENTS
Estimated Expiration: ⤷ Subscribe

South Korea

Patent: 1748892
Estimated Expiration: ⤷ Subscribe

Patent: 1926060
Estimated Expiration: ⤷ Subscribe

Patent: 1976107
Estimated Expiration: ⤷ Subscribe

Patent: 120015334
Patent: COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS
Estimated Expiration: ⤷ Subscribe

Patent: 120026075
Patent: RESPIRATORY DELIVERY OF ACTIVE AGENTS
Estimated Expiration: ⤷ Subscribe

Patent: 120034631
Patent: COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS
Estimated Expiration: ⤷ Subscribe

Patent: 170070274
Patent: 지속형 무스카린 안타고니스트 및 지속형 Ｂ₂아드레날린 수용체 아고니스트의 폐 전달용 조성물, 및 연관된 방법 및 시스템 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 170104003
Patent: 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 180130602
Patent: 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 190049943
Patent: 활성제의 호흡기 전달 (RESPIRATORY DELIVERY OF ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Spain

Patent: 89135
Estimated Expiration: ⤷ Subscribe

Patent: 92536
Estimated Expiration: ⤷ Subscribe

Patent: 93429
Estimated Expiration: ⤷ Subscribe

Patent: 72253
Estimated Expiration: ⤷ Subscribe

Patent: 74367
Estimated Expiration: ⤷ Subscribe

Patent: 74391
Estimated Expiration: ⤷ Subscribe

Taiwan

Patent: 39979
Estimated Expiration: ⤷ Subscribe

Patent: 46094
Estimated Expiration: ⤷ Subscribe

Patent: 32926
Estimated Expiration: ⤷ Subscribe

Patent: 33898
Estimated Expiration: ⤷ Subscribe

Patent: 46980
Estimated Expiration: ⤷ Subscribe

Patent: 95723
Estimated Expiration: ⤷ Subscribe

Patent: 07700
Estimated Expiration: ⤷ Subscribe

Patent: 17511
Estimated Expiration: ⤷ Subscribe

Patent: 92140
Estimated Expiration: ⤷ Subscribe

Patent: 1109049
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 1109050
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting &bgr;2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 1109051
Patent: Compositions, methods and systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷ Subscribe

Patent: 1642836
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting [beta]2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 1700123
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 1808372
Patent: Compositions, methods and systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷ Subscribe

Patent: 1919730
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 1936174
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting [beta]2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 2114642
Patent: Compositions, methods and systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷ Subscribe

Ukraine

Patent: 9529
Patent: КОМПОЗИЦІЇ ДЛЯ РЕСПІРАТОРНОЇ ДОСТАВКИ АКТИВНИХ АГЕНТІВ ТА ПОВ'ЯЗАНІ СПОСОБИ І СИСТЕМИ
Estimated Expiration: ⤷ Subscribe

Patent: 9530
Patent: КОМПОЗИЦІЇ, СПОСОБИ ТА СИСТЕМИ ДЛЯ ДОСТАВКИ РЕСПІРАТОРНИМ ШЛЯХОМ ДВОХ ЧИ БІЛЬШЕ АКТИВНИХ АГЕНТІВ
Estimated Expiration: ⤷ Subscribe

Patent: 9531
Patent: КОМПОЗИЦІЇ ДЛЯ ЛЕГЕНЕВОЇ ДОСТАВКИ МУСКАРИНОВИХ АНТАГОНІСТІВ ТРИВАЛОЇ ДІЇ ТА АГОНІСТІВ АДРЕНЕРГІЧНИХ РЕЦЕПТОРІВ B2 ТРИВАЛОЇ ДІЇ ТА ПОВ'ЯЗАНІ СПОСОБИ І СИСТЕМИ
Estimated Expiration: ⤷ Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYMBICORT AEROSPHERE around the world.

Subscribe to access the full database, or Subscribe
Country	Patent Number	Title	Estimated Expiration
Japan	2018008942	活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 (COMPOSITION FOR RESPIRATORY DELIVERY OF ACTIVE AGENT, AND RELATED METHOD AND SYSTEM)	⤷ Subscribe
Ukraine	109529	КОМПОЗИЦІЇ ДЛЯ РЕСПІРАТОРНОЇ ДОСТАВКИ АКТИВНИХ АГЕНТІВ ТА ПОВ'ЯЗАНІ СПОСОБИ І СИСТЕМИ	⤷ Subscribe
South Korea	20120015334		⤷ Subscribe
Russian Federation	2015151358	КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ В2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ	⤷ Subscribe
Russian Federation	2011154148		⤷ Subscribe
Hong Kong	1169307	經由呼吸道遞送活性藥劑 (RESPIRATORY DELIVERY OF ACTIVE AGENTS)	⤷ Subscribe
Australia	2015201037		⤷ Subscribe
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for SYMBICORT AEROSPHERE

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	122021000026	Germany	⤷ Subscribe	PRODUCT NAME: GLYCOPYRROLAT MIT FORMOTEROL MIT BUDESONID, ODER SALZE, ESTER, SOLVATE, ENANTIOMERE UND MISCHUNGEN VON ENANTIOMEREN DERSELBEN; REGISTRATION NO/DATE: EU/1/20/1498 20201209
2435024	LUC00208	Luxembourg	⤷ Subscribe	PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), DE GLYCOPYRRONIUM (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE BUDESONIDE (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1468 20201210
2435025	122019000068	Germany	⤷ Subscribe	PRODUCT NAME: KOMBINATION VON GLYCOPYRROLAT, EINSCHLIESSLICH BELIEBIGER PHARMAZEUTISCH VERTRAEGLICHER SALZE, ESTER, ENANTIOMERE, ODER ANDERER DERIVATE DAVON, UND FORMOTEROL, EINSCHLIESSLICH BELIEBIGER PHARMAZEUTISCH VERTRAEGLICHER SALZE, ESTER, ENANTIOMERE, ODER ANDERER DERIVATE DAVON; REGISTRATION NO/DATE: EU/1/18/1339 20181218
2435024	132021000000095	Italy	⤷ Subscribe	PRODUCT NAME: UNA COMBINAZIONE DI FORMOTEROLO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI), GLICOPIRROLATO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI) E BUDESONIDE (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI)(TRIXEO AEROSPHERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1498, 20201210
2435025	PA2019014,C2435025	Lithuania	⤷ Subscribe	PRODUCT NAME: GLIKOPIRONIO BROMIDAS/FORMOTEROLIS; REGISTRATION NO/DATE: EU/1/18/1339 20181218
2435024	PA2021511,C2435024	Lithuania	⤷ Subscribe	PRODUCT NAME: FORMOTEROLIO (ISKAITANT BET KOKIAS FARMACINIU POZIURIU PRIIMTINAS JO DRUSKAS, ESTERIUS, SOLVATUS ARBA ENATIOMERUS), GLIKOPIROLATO (ISKAITANT BET KOKIAS FARMACINIU POZIURIU PRIIMTINAS JO DRUSKAS, ESTERIUS, SOLVATUS ARBA ENANTIOMERUS) IR BUDEZONIDO (ISKAITANT BET KOKIAS FARMACINIU POZIURIU PRIIMTINAS JO DRUSKAS, ESTERIUS, SOLVATUS ARBA ENATIOMERUS) DERINYS; REGISTRATION NO/DATE: EU/1/20/1498 20201209
2435024	2021C/518	Belgium	⤷ Subscribe	PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

SYMBICORT AEROSPHERE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for SYMBICORT AEROSPHERE

Introduction

SYMBICORT AEROSPHERE, a combination of budesonide and formoterol fumarate, is a widely used inhalation aerosol for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) and, in some cases, asthma. Here, we delve into the market dynamics and financial trajectory of this medication.

Market Overview

The global market for asthma and COPD therapeutics is projected to reach $44.1 billion by 2031, growing at a CAGR of 7.3% over the forecast period. This growth is driven by the increasing prevalence of respiratory diseases worldwide and the availability of low-cost prescription drugs[1].

Product Positioning

SYMBICORT AEROSPHERE is indicated for the maintenance treatment of COPD and is not intended for the relief of acute bronchospasm or the treatment of asthma. It combines a corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (LABA, formoterol fumarate), making it a significant player in the COPD therapeutics segment[5].

Sales Performance

Historically, SYMBICORT has been a strong performer in AstraZeneca's respiratory portfolio. In 2018, SYMBICORT sales in China increased by 36% (32% at constant exchange rates) to $240 million, contributing significantly to AstraZeneca's overall revenue[4].

Competitive Landscape

The COPD therapeutics market is highly competitive, with several key players. Boehringer’s Spiriva has been a major player, while new entrants like GSK’s Incruse Ellipta and Boehringer’s Stiolto Respimat are expected to gain market share during the forecast period. AstraZeneca’s own portfolio, including SYMBICORT, faces competition from these new products but remains a significant force due to its established presence and ongoing innovations[1].

Pricing and Accessibility

AstraZeneca has taken steps to improve the accessibility of its respiratory medications, including SYMBICORT. Starting June 1, 2024, eligible patients in the U.S. will pay no more than $35 per month for all AstraZeneca inhaled respiratory medicines, including SYMBICORT. This move is aimed at reducing the financial burden on patients and ensuring better adherence to treatment plans[3].

Financial Impact

The financial performance of SYMBICORT is closely tied to AstraZeneca's overall respiratory portfolio. In recent years, AstraZeneca has seen significant growth in its respiratory segment, with total revenue from these medicines contributing substantially to the company's bottom line. For instance, in 2018, Pulmicort and SYMBICORT sales were key drivers of revenue growth in the respiratory segment[4].

Geographical Performance

SYMBICORT has performed well in various geographical regions. In emerging markets, particularly China, the drug has seen considerable growth. In 2018, China sales of SYMBICORT increased by 36%, reflecting the growing demand for respiratory treatments in these regions[4].

Challenges and Opportunities

Despite its strong market position, SYMBICORT faces challenges such as competitive pressure from new market entrants and potential changes in reimbursement policies. However, AstraZeneca's commitment to research and development, as well as its efforts to enhance patient access and affordability, are expected to mitigate these challenges and drive continued growth.

Future Outlook

The future outlook for SYMBICORT is positive, driven by the increasing prevalence of COPD and the need for effective maintenance treatments. AstraZeneca's strategic initiatives, such as capping patient out-of-pocket costs and investing in next-generation biologics and novel mechanisms, are expected to support the continued success of SYMBICORT in the market.

Key Takeaways

Market Growth: The global market for asthma and COPD therapeutics is expected to grow significantly, driven by increasing disease prevalence and availability of low-cost drugs.
Product Positioning: SYMBICORT AEROSPHERE is a key player in the COPD therapeutics segment, combining a corticosteroid and a LABA.
Sales Performance: SYMBICORT has historically performed well, particularly in emerging markets like China.
Competitive Landscape: The market is competitive, but AstraZeneca's ongoing innovations and accessibility initiatives support SYMBICORT's market position.
Financial Impact: SYMBICORT contributes significantly to AstraZeneca's respiratory segment revenue.
Geographical Performance: The drug has seen strong growth in various regions, including emerging markets.
Challenges and Opportunities: Despite competitive pressures, AstraZeneca's strategies are expected to drive continued growth.

FAQs

Q: What is the primary indication for SYMBICORT AEROSPHERE? A: SYMBICORT AEROSPHERE is primarily indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)[5].

Q: How is AstraZeneca improving patient access to SYMBICORT AEROSPHERE? A: Starting June 1, 2024, AstraZeneca will cap patient out-of-pocket costs for SYMBICORT AEROSPHERE at $35 per month for eligible patients in the U.S.[3].

Q: What are the key competitors to SYMBICORT AEROSPHERE in the COPD therapeutics market? A: Key competitors include Boehringer’s Spiriva, GSK’s Incruse Ellipta, and Boehringer’s Stiolto Respimat[1].

Q: How has SYMBICORT AEROSPHERE performed in emerging markets? A: SYMBICORT AEROSPHERE has seen significant growth in emerging markets, particularly in China, where sales increased by 36% in 2018[4].

Q: What are the future prospects for SYMBICORT AEROSPHERE in the market? A: The future outlook is positive, driven by increasing disease prevalence and AstraZeneca's strategic initiatives to enhance patient access and affordability.

Cited Sources

Global Asthma and COPD Therapeutics Market $44.1 Billion by 2031 - iHealthcareAnalyst
Full year and Q4 2022 results | AstraZeneca - AstraZeneca
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio - AstraZeneca US
Full-year and Q4 2018 results - AstraZeneca - AstraZeneca
SYMBICORT AEROSPHERE - accessdata.fda.gov - FDA

More… ↓

⤷ Subscribe

Indicators of Generic Entry

AI Research Assistant

Questions you can ask:

Summary for SYMBICORT AEROSPHERE

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SYMBICORT AEROSPHERE

When does loss-of-exclusivity occur for SYMBICORT AEROSPHERE?

SYMBICORT AEROSPHERE Market Analysis and Financial Projection Experimental

Introduction

Market Overview

Product Positioning

Sales Performance

Competitive Landscape

Pricing and Accessibility

Financial Impact

Geographical Performance

Challenges and Opportunities

Future Outlook

Key Takeaways

FAQs

Cited Sources

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SYMBICORT AEROSPHERE